Skip to main content
. Author manuscript; available in PMC: 2019 Sep 19.
Published in final edited form as: J Neurooncol. 2019 Jan 24;142(2):337–345. doi: 10.1007/s11060-019-03102-5

Fig. 1.

Fig. 1

Time to progression on bevacizumab by a TCGA subtype b EGFR amplification status. Kaplan–Meier curve for time to progression on bevacizumab stratified by TCGA subtype (a) and EGFR amplification status (b)